I now have comprehensive information from multiple authoritative textbooks. Here is the full answer:
Differentiating HFpEF from HFrEF
The definitive distinction requires echocardiography (LVEF ≥50% = HFpEF; LVEF <40% = HFrEF; LVEF 40-49% = HFmrEF). However, several clinical features point strongly toward one or the other before the echo result is available.
1. The LVEF Cut-offs (Formal Definitions)
| Category | LVEF | Old Terminology |
|---|
| HFrEF | < 40% | Systolic HF |
| HFmrEF | 40-49% | Mildly reduced EF |
| HFpEF | ≥ 50% | Diastolic HF |
2. Clinical Profile: Who Gets Each?
| Feature | HFpEF | HFrEF |
|---|
| Age | Older (typically >65) | Any age |
| Sex | More commonly female | More commonly male |
| Hypertension | Present in 60-80% | Less dominant |
| Prior MI / CAD | Less common | Frequent antecedent cause |
| Obesity / Diabetes | Strongly associated | Less strongly associated |
| Atrial fibrillation | Very common (often paroxysmal) | Common (often persistent) |
| CKD / COPD | High comorbidity burden | Less so |
| Cardiomyopathy history | Rare | Common (dilated, ischemic) |
Key pearl: An older, obese woman with longstanding hypertension and new dyspnea is HFpEF until proven otherwise. A middle-aged man with prior anterior MI and declining exercise capacity is HFrEF until proven otherwise.
3. Heart Sounds - the Most Useful Bedside Clue
| Finding | HFpEF | HFrEF |
|---|
| S4 gallop | Characteristic (stiff, non-compliant LV requires forceful atrial kick) | Less prominent |
| S3 gallop | Absent or rare | Classic - indicates dilated, volume-overloaded ventricle |
| Murmurs | Mitral regurgitation may occur | MR common (functional); TR may develop |
4. Chest X-Ray
| Finding | HFpEF | HFrEF |
|---|
| Cardiomegaly | Often absent - do not be fooled into excluding HF because the cardiac silhouette is normal | Almost always present |
| Pulmonary congestion | Present when decompensated | Present when decompensated |
5. Echocardiographic Features
| Finding | HFpEF | HFrEF |
|---|
| LVEF | ≥50% (normal/preserved contraction) | <40% (impaired contraction) |
| LV cavity size | Usually normal or small | Usually dilated |
| LV wall thickness | Often increased (concentric hypertrophy) | Thinned or normal |
| LV geometry | Concentric remodeling/hypertrophy | Eccentric dilation |
| Diastolic indices | Elevated E/e' ratio, reduced e' velocity (Grade II-III diastolic dysfunction) | Variable |
6. Pathophysiology Behind the Differences
-
HFrEF: The problem is systolic - the ventricle cannot contract adequately. Cardiac output falls, the ventricle dilates and remodels, and neurohormonal activation (RAAS, SNS) worsens the cycle.
-
HFpEF: The problem is diastolic - contraction is normal but the ventricle is stiff and cannot relax or fill properly. Resting hemodynamics may be near-normal, but during exercise or tachycardia (e.g., from AF), filling pressures spike dramatically, causing dyspnea. Because atrial contraction contributes disproportionately to filling of a stiff ventricle, loss of atrial kick in AF is particularly poorly tolerated. Patients also have a narrow "euvolemic window" - even modest fluid overload causes severe dyspnea, yet aggressive diuresis causes underfilling and hypotension.
7. BNP / NT-proBNP
Both forms elevate natriuretic peptides when decompensated. However, BNP levels are often lower in HFpEF than in HFrEF for the same degree of symptoms, because the smaller, stiffer LV generates less wall stress. Obesity (common in HFpEF) further suppresses BNP levels, which can mislead clinicians.
8. Response to Therapy - A Diagnostic Clue in Retrospect
| Drug class | HFrEF | HFpEF |
|---|
| ACE inhibitors / ARBs | Mortality benefit proven | No mortality benefit |
| Beta-blockers | Mortality benefit proven | No proven mortality benefit |
| Aldosterone antagonists | Strong benefit | Modest HF hospitalization reduction only |
| SGLT-2 inhibitors | Benefit (empagliflozin, dapagliflozin) | Benefit (empagliflozin in EMPEROR-Preserved) |
| Diuretics | Symptom control | Symptom control, but risk of over-diuresis |
Quick Summary Table
| HFpEF | HFrEF |
|---|
| LVEF | ≥50% | <40% |
| Ventricle | Small, stiff, hypertrophied | Dilated, thin-walled |
| Typical patient | Old, female, hypertensive, obese | Male, post-MI or cardiomyopathy |
| S3 gallop | Absent | Present |
| S4 gallop | Present | Absent |
| Cardiomegaly on CXR | Often absent | Usually present |
| AF | Very common, paroxysmal | Common, persistent |
| Diuresis risk | Over-diuresis dangerous | Better tolerated |
Bottom line: echo is the arbiter. Clinically, the combination of patient demographics (older, female, hypertensive), preserved cardiac size on CXR, S4 (not S3), and preserved contraction on bedside assessment should raise strong suspicion for HFpEF - but you cannot reliably confirm it without measuring LVEF.
Sources: Swanson's Family Medicine Review, p. 127; Braunwald's Heart Disease, Chapter 51; Goldman-Cecil Medicine, Chapter 45; Harrison's Principles of Internal Medicine 22E, Chapter 28